TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02343289
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
Study: NCT00658905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One week treatment
Study: NCT01495572
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV (in the vein) for days -7 and -6
Study: NCT00636740
Drug: Zoledronic Acid 20mg Tablets
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral enteric coated tablets, 20mg, weekly, 8 weeks
Study: NCT00636740
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
Study: NCT00636740
Drug: Zoledronic Acid 20mg Tablets
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
Study: NCT01888549
Drug: High-dose PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: :40mg, po(per oral) 2times.day, 8weeks
Study: NCT01888549
Drug: standard PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: : 40mg, po(per oral) 1times.day, 8weeks
Study: NCT01888549
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01580553
Drug: Levocarnitine Injection
Normalized name: levocarnitine Injection
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine Injection:5ml:1g
Study: NCT01580553
Drug: Levocarnitine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine injection placebo (5ml:1g)
Study: NCT00649493
Drug: Aciphex® Tablets 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, single dose fed
Study: NCT03482817
Drug: Ze 117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
Study: NCT02374593
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
Study: NCT02826382
Drug: [68Ga]P15-041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041
Study: NCT01830881
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Study: NCT02753725
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
Study: NCT02614547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as intravenous infusion.
Study: NCT02753725
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
Study: NCT00736073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
Study: NCT00734214
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Fluid~Isotonic Parenteral Fluid
Study: NCT02038764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01681615
Drug: Isotonic NaCl
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop
Study: NCT01214993
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
Study: NCT01214993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a tablet with no drug in it.
Study: NCT02314689
Drug: Intravenous (IV) citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00788242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
Study: NCT02413281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets, single administration
Study: NCT03551691
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically-appearing capsule to omeprazole for 28 days
Study: NCT00994175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00197093
Drug: SB773812
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01227291
Drug: SYL040012
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYL040012 ophthalmic drops, daily single dose administration
Study: NCT04091698
Drug: Co-Enzyme Q10 mucoadhesive tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
Study: NCT00368108
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT02666664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Study: NCT02432664
Drug: ODM-108 Part I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
Study: NCT02432664
Drug: ODM-108 Part III
Normalized name: CARDIOTOXIN III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules 1 - 4 times daily for 7 to 10 days
Study: NCT01425632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02369471
Drug: GWP42006
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00629031
Drug: Paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11 mg/kg for 14 days
Study: NCT04055168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
Study: NCT02369471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00129935
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00129935
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03514615
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The incision site on the other arm will be dosed with placebo gel.
Study: NCT03076905
Drug: F901318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of AUC0-t
Study: NCT02797522
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
Study: NCT00629031
Drug: Paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin for 21 days @ 11mg/kg by intramuscular injections
Study: NCT03159585
Drug: TAEST16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
Study: NCT02710331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: no alcohol, administered for \~80 minutes.
Study: NCT02710331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Placebo pill (no active cannabinoids) administered orally.
Study: NCT02710331
Drug: Active Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
Study: NCT00551330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of placebo once daily
Study: NCT02330094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications.
Study: NCT03487198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2-3 mg/day
Study: NCT04645524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule administered before bed
Study: NCT00786201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
Study: NCT00786201
Drug: CNTO 888 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Study: NCT00786201
Drug: CNTO 888 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Study: NCT00786201
Drug: CNTO 888 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Study: NCT00363896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
Study: NCT00999505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice a day over 12 weeks
Study: NCT00081575
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003877
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01168063
Drug: standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)
Normalized name: pantoprazole, amoxicillin, clarithromycin and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 lines of treatments :~1) PPI + Amoxicillin + Clarithromycin for 7 days~1) PPI + Amoxicillin + Metronidazole for 14 days
Study: NCT00560144
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg iv weekly
Study: NCT00560144
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9mg/kg iv weekly
Study: NCT00560144
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic-derived dose, \<=16mg/kg iv weekly
Study: NCT04481685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill will be taken twice daily preferably spaced 12 hours apart.
Study: NCT00136643
Drug: Invisible Condom®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04341129
Drug: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To test the diagnostic effectiveness of an abbreviated MRI to a full MRI in the evaluation of breast lesions using Dotarem
Study: NCT00806481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group: treatment with tablets of placebo three times daily for 36 weeks
Study: NCT00708318
Drug: i.v. fentanyl and AeroLEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN.
Study: NCT01428427
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
Study: NCT03822429
Drug: Controlled ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal therapy to induce ovulation by multiple ovarian follicles
Study: NCT00504777
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg/week po or parenteral
Study: NCT00416195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00505154
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10 mg tablets od for 6 months
Study: NCT00505154
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04154852
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01417104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg/300mg
Study: NCT00639522
Drug: Liposomal paclitaxel and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
Study: NCT02718261
Drug: Saline 0.9% (matching placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01589159
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug:capecitabine 700mg/m2, twice daily on days 1-14.
Study: NCT04089189
Drug: IMP4297
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP4297 100mg PO QD
Study: NCT01055847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Placebo
Study: NCT03274895
Drug: PHMB 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
Study: NCT03508804
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml of vaginally self-administered placebo cream
Study: NCT01435044
Drug: Placebo to match GS-0938
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GS-0938 administered orally once daily
Study: NCT04012177
Drug: Azithromycin Tablets
Normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
Study: NCT01501422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch for 8 weeks
Study: NCT04012177
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
Study: NCT02927353
Drug: DMB-3113
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously injected in a single dose of 40 mg.
Study: NCT01987492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
Study: NCT00757627
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 60 mg QD for 4 weeks.
Study: NCT01133080
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
Study: NCT01133080
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.
Study: NCT00002653
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00536653
Drug: Bicalutamide and Calcium/ Vitamin D supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
Study: NCT00536653
Drug: LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
Study: NCT01912404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo controlled
Study: NCT00309257
Drug: ACE I, ATA II and Statins
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00499967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GS-9191 ointment
Study: NCT00309257
Drug: Benazepril, Valsartan and Fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate.
Study: NCT03054740
Drug: Nature's Tears
Normalized name: Nature's Tears
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water mist will be administered 1-2 sprays prior to intravenous access
Study: NCT03156855
Drug: 14-day sequential therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
Study: NCT01327846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01327846
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
Study: NCT00219479
Drug: Phenytoin (Dilantin) levels during change in enteral feeding
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01843725
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: escalation dose of capecitabine continuously
Study: NCT01843725
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
Study: NCT01635023
Drug: AZD6244 Dosing Period 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A, B, or C depending on randomization assignment
Study: NCT01079910
Drug: isopropylmethylphenol and Fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% isopropylmethylphenol and 1150ppm fluoride
Study: NCT02448329
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1\~3
Study: NCT02714283
Drug: inhaled corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
Study: NCT02714283
Drug: macrolide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
Study: NCT01509547
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
Study: NCT03365947
Drug: ARO-HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc injection
Study: NCT00594880
Drug: Pegylated Interferon-alpha 2a, 180 mcg/week sc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
Study: NCT00594880
Drug: Pegylated Interferon-alpha 2a, 90 mcg/week sc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
Study: NCT00006158
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02387554
Drug: HGP0904
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02387554
Drug: HGP0608
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02387554
Drug: HGP1405
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02142153
Drug: F901318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile
Study: NCT02142153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
Study: NCT00022737
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV